Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 12.77
NVIV's Cash to Debt is ranked higher than
78% of the 519 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. NVIV: 12.77 )
NVIV' s 10-Year Cash to Debt Range
Min: 0.11   Max: No Debt
Current: 12.77

F-Score: 2
Z-Score: 3.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -275.30
NVIV's ROE (%) is ranked lower than
56% of the 488 Companies
in the Global Medical Devices industry.

( Industry Median: 4.73 vs. NVIV: -275.30 )
NVIV' s 10-Year ROE (%) Range
Min: -775.86   Max: -195.09
Current: -275.3

-775.86
-195.09
ROA (%) -144.40
NVIV's ROA (%) is ranked lower than
56% of the 522 Companies
in the Global Medical Devices industry.

( Industry Median: 1.71 vs. NVIV: -144.40 )
NVIV' s 10-Year ROA (%) Range
Min: -1218.1   Max: 42.86
Current: -144.4

-1218.1
42.86
ROC (Joel Greenblatt) (%) -1016.86
NVIV's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 517 Companies
in the Global Medical Devices industry.

( Industry Median: 7.57 vs. NVIV: -1016.86 )
NVIV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3330.38   Max: -817.6
Current: -1016.86

-3330.38
-817.6
EBITDA Growth (3Y)(%) -33.30
NVIV's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. NVIV: -33.30 )
NVIV' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -62.2   Max: 543.1
Current: -33.3

-62.2
543.1
EPS Growth (3Y)(%) -32.30
NVIV's EPS Growth (3Y)(%) is ranked higher than
59% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: -2.50 vs. NVIV: -32.30 )
NVIV' s 10-Year EPS Growth (3Y)(%) Range
Min: -62.2   Max: 544.7
Current: -32.3

-62.2
544.7
» NVIV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NVIV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 33.20
NVIV's P/B is ranked lower than
64% of the 582 Companies
in the Global Medical Devices industry.

( Industry Median: 3.93 vs. NVIV: 33.20 )
NVIV' s 10-Year P/B Range
Min: 0   Max: 67.4
Current: 33.2

0
67.4
EV-to-EBIT -17.07
NVIV's EV-to-EBIT is ranked higher than
71% of the 582 Companies
in the Global Medical Devices industry.

( Industry Median: 568.20 vs. NVIV: -17.07 )
NVIV' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -17.07

Current Ratio 1.68
NVIV's Current Ratio is ranked higher than
57% of the 516 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. NVIV: 1.68 )
NVIV' s 10-Year Current Ratio Range
Min: 0.14   Max: 14.81
Current: 1.68

0.14
14.81
Quick Ratio 1.68
NVIV's Quick Ratio is ranked higher than
66% of the 516 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. NVIV: 1.68 )
NVIV' s 10-Year Quick Ratio Range
Min: 0.14   Max: 14.81
Current: 1.68

0.14
14.81

Valuation & Return

vs
industry
vs
history
Price/Net Cash 42.80
NVIV's Price/Net Cash is ranked higher than
77% of the 582 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NVIV: 42.80 )
NVIV' s 10-Year Price/Net Cash Range
Min: 4.72   Max: 48
Current: 42.8

4.72
48
Price/Net Current Asset Value 42.80
NVIV's Price/Net Current Asset Value is ranked higher than
65% of the 582 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NVIV: 42.80 )
NVIV' s 10-Year Price/Net Current Asset Value Range
Min: 4.44   Max: 36
Current: 42.8

4.44
36
Price/Tangible Book 32.90
NVIV's Price/Tangible Book is ranked lower than
64% of the 582 Companies
in the Global Medical Devices industry.

( Industry Median: 7.69 vs. NVIV: 32.90 )
NVIV' s 10-Year Price/Tangible Book Range
Min: 3.96   Max: 19.38
Current: 32.9

3.96
19.38
Earnings Yield (Greenblatt) -6.10
NVIV's Earnings Yield (Greenblatt) is ranked higher than
55% of the 507 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. NVIV: -6.10 )
NVIV' s 10-Year Earnings Yield (Greenblatt) Range
Min: -29.4   Max: 1000
Current: -6.1

-29.4
1000

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
InVivo Therapeutics Holdings Corp. was incorporated on April 2, 2003, under the name of Design Source, Inc. The Company develops novel biomaterial technologies for the treatment of spinal cord injuries and hydrogels for therapeutics delivery. It is also developing an injectable, resorbable family of hydrogels for localized, controlled release of small molecules and proteins. Under the CMCC License, the Company has the right to sublicense the patents and have full control and authority over the development and commercialization of the licensed products, including clinical trials, manufacturing, marketing, and regulatory filings. The Comany also own the rights to the data generated pursuant to the CMCC License. The Company competes with major drug companies, specialized biotechnology firms, academic institutions, government agencies and private and public research institutions. The Company is subject to evolving federal, state and local environmental, health and safety laws and regulations.
» More Articles for NVIV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
InVivo Therapeutics Announces Indiana’s Goodman Campbell Brain and Spine as New Site for... May 19 2015
InVivo Therapeutics Announces Indiana’s Goodman Campbell Brain and Spine as New Site for... May 19 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Financials May 15 2015
NVIV: Explaining InVivo's Neuro-Spinal Scaffold Update May 14 2015
InVivo Therapeutics Reports Update of First Two Spinal Cord Injury Patients Implanted with... May 14 2015
InVivo Therapeutics Reports Update of First Two Spinal Cord Injury Patients Implanted with... May 14 2015
10-Q for Invivo Therapeutics Holdings Corp. May 09 2015
InVivo Therapeutics Reports 2015 First Quarter Financial Results and Business Update May 07 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 10-Q, Quarterly Report May 07 2015
10-K for Invivo Therapeutics Holdings Corp. May 06 2015
InVivo Therapeutics to Exhibit at the 83rd AANS Annual Scientific Meeting May 01 2015
InVivo Therapeutics to Exhibit at the 83rd AANS Annual Scientific Meeting May 01 2015
Four one-time biotech underdogs are outperforming the market this year Apr 22 2015
Coverage initiated on InVivo Therapeutics by H.C. Wainwright Apr 17 2015
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) to Ring The Nasdaq Stock Market Opening Bell Apr 16 2015
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) to Ring The Nasdaq Stock Market Opening Bell Apr 16 2015
InVivo Therapeutics Announces Uplisting to Nasdaq Apr 16 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Other Events, Financial Statements and... Apr 16 2015
InVivo Therapeutics Announces Uplisting to Nasdaq Apr 16 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Other Events Apr 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK